Literature DB >> 19892024

HLA-haploidentical stem cell transplantation for hematologic malignancies.

Ephraim J Fuchs1, Xiao-jun Huang, Jeffrey S Miller.   

Abstract

Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19892024      PMCID： PMC2832726          DOI： 10.1016/j.bbmt.2009.10.032

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  40 in total

1.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.

Authors:  Stella M Davies; Loredana Ruggieri; Todd DeFor; John E Wagner; Daniel J Weisdorf; Jeffrey S Miller; Andrea Velardi; Bruce R Blazar
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

2.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

3.  Marrow transplantation from related donors other than HLA-identical siblings.

Authors:  P G Beatty; R A Clift; E M Mickelson; B B Nisperos; N Flournoy; P J Martin; J E Sanders; P Stewart; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

4.  HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease.

Authors:  R J O'Reilly; C Keever; N A Kernan; J Brochstein; N Collins; N Flomenberg; J Laver; D Emanuel; B Dupont; I Cunningham
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

5.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

Authors:  C Anasetti; P G Beatty; R Storb; P J Martin; M Mori; J E Sanders; E D Thomas; J A Hansen
Journal:  Hum Immunol       Date:  1990-10       Impact factor: 2.850

6.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

Authors:  Yoshinobu Kanda; Shigeru Chiba; Hisamaru Hirai; Hisashi Sakamaki; Tohru Iseki; Yoshihisa Kodera; Takahiro Karasuno; Shinichiro Okamoto; Noriyuki Hirabayashi; Koji Iwato; Atsuo Maruta; Yoshihiro Fujimori; Tatsuo Furukawa; Shin Mineishi; Keitaro Matsuo; Nobuyuki Hamajima; Masahiro Imamura
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

7.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

8.  Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect.

Authors:  Song-He Chen; Xin Li; Xiao-Jun Huang
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

9.  Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion.

Authors:  R C Ash; M M Horowitz; R P Gale; D W van Bekkum; J T Casper; E C Gordon-Smith; P J Henslee; H J Kolb; B Lowenberg; T Masaoka
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

10.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

Authors:  C Anasetti; D Amos; P G Beatty; F R Appelbaum; W Bensinger; C D Buckner; R Clift; K Doney; P J Martin; E Mickelson
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245
View more
  15 in total

1.  Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance.

Authors:  Suzanne T Ildstad; Joseph Leventhal; Yujie Wen; Esma Yolcu
Journal:  Chimerism       Date:  2016-01-08

2.  Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Authors:  Isabel Barao; Maite Alvarez; Erik Ames; Mark T Orr; Heather E Stefanski; Bruce R Blazar; Lewis L Lanier; Stephen K Anderson; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

3.  Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Authors:  Diego Sánchez-Martínez; Gemma Azaceta; Aura Muntasell; Nacho Aguiló; David Núñez; Eva M Gálvez; Javier Naval; Alberto Anel; Luis Palomera; Carlos Vilches; Isabel Marzo; Martín Villalba; Julián Pardo
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

4.  Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.

Authors:  Eunsun Yoo; Laura A Paganessi; Wasfia A Alikhan; Elizabeth A Paganessi; Frank Hughes; Henry C Fung; Elizabeth Rich; Chu Myong Seong; Kent W Christopherson
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

Review 5.  Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.

Authors:  J Leventhal; J Miller; M Abecassis; D J Tollerud; S T Ildstad
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875

6.  Differential expression of the Ly49G(B6), but not the Ly49G(BALB), receptor isoform during natural killer cell reconstitution after hematopoietic stem cell transplantation.

Authors:  Isabel Barao; Paul W Wright; Can M Sungur; Stephen K Anderson; Doug Redelman; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-31       Impact factor: 5.742

7.  Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

Authors:  Andres Wiernik; Bree Foley; Bin Zhang; Michael R Verneris; Erica Warlick; Michelle K Gleason; Julie A Ross; Xianghua Luo; Daniel J Weisdorf; Bruce Walcheck; Daniel A Vallera; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2013-05-20       Impact factor: 12.531

8.  Assessing Early Supportive Care Needs among Son or Daughter Haploidentical Transplantation Donors.

Authors:  Nina D Wagner-Johnston; Susan M Hannum; JaAlah-Ai Heughan; Martha Abshire; Jennifer L Wolff; Kathryn Yarkony; Heather Symons; Richard J Jones; Sydney M Dy
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-08       Impact factor: 5.742

Review 9.  Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Authors:  Meng Lv; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

10.  HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.

Authors:  X-Y Zhao; Y-J Chang; L-P Xu; X-H Zhang; K-Y Liu; D Li; X-J Huang
Journal:  Br J Cancer       Date:  2014-07-31       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.